DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system

DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system

IntroductionDNA methylation inhibitors have been approved for the prevention of Acute Myeloid Leukemia (AML), and their safety profile is not fully characterized. This study was aimed at evaluating the adverse drug reactions (ADRs) of DNA methylation inhibitors by analyzing the individual case safet...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xia Zhang, Yuyu Liu, Qingwang Hou, Yongxin Guo, Youfu He
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Pharmacology
Subjects:	DNA methylation inhibitors adverse drug reactions system organ class eudravigilance database comparative observational study azacitidine
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1527903/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Data mining and analysis of adverse events of Vedolizumab based on the FAERS database
by: Qinyun Xu, et al.
Published: (2025-01-01)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
by: Shaimaa Elshafie, et al.
Published: (2025-01-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database
by: Shuai Zhao, et al.
Published: (2025-02-01)

Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system
by: Shiyi Wang, et al.
Published: (2025-02-01)

Root Cause Analysis of Adverse Outcomes in the Obstetrics & Gynaecology: A Prospective Study at a Tertiary Care Centre
by: Brijesh Narayan, et al.
Published: (2024-12-01)

Typological and cumulative approaches to risk and adversity in Child and Adolescent Mental Health Services (CAMHS): Retrospective cohort analysis in South London
by: Barry Coughlan, et al.
Published: (2025-02-01)

Precision Adverse Drug Reactions Prediction with Heterogeneous Graph Neural Network
by: Yang Gao, et al.
Published: (2025-01-01)

Antibiotics-induced pulmonary embolism: A disproportionality analysis in Food and Drug Administration database of Adverse Event Reporting System using data mining algorithms
by: Pramod Kumar Adusumilli, et al.
Published: (2025-01-01)

A disproportionality analysis of FDA adverse event reporting system events for misoprostol
by: Li Yang, et al.
Published: (2025-01-01)

Adverse Reactions from Topical Ophthalmic Anesthetic Abuse
by: Ali Sharifi, et al.
Published: (2022-11-01)

Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system
by: Jingrong Yang, et al.
Published: (2025-01-01)

Risk factors for severe adverse drug reactions in hospitalized patients
by: Petrović Nemanja Z., et al.
Published: (2025-01-01)

Safety of combined drug use in patients with cardiovascular and cerebrovascular diseases: an analysis based on the spontaneous reporting database of adverse drug reactions in Hubei Province
by: Jia Wang, et al.
Published: (2025-01-01)

Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01)

Thai Passive Markers in Adversative and Non-adversative Passives in Speakers of Different Ages
by: Indrambarya, Kitima
Published: (2025-01-01)

Analysis of the effectiveness of premedication in preventing early adverse reactions to antivenom serum from 2017 to 2021: A cohort study
by: Gustavo Abud Priedols, et al.
Published: (2025-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
by: Jenna L. Carter, et al.
Published: (2025-01-01)

Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis
by: Zixian Yu, et al.
Published: (2025-01-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system
by: Ruichen Gao, et al.
Published: (2025-02-01)

A meta-analysis of risk factors for cardiovascular adverse events with anthracycline based chemotherapy in lymphoma patients
by: Bo Dai, et al.
Published: (2025-01-01)

Rare skin adverse reactions induced by osimertinib: a case report and literature review
by: Ye Zhang, et al.
Published: (2025-01-01)

Heart disease in pregnancy and adverse outcomes: an umbrella review
by: Jiani Zhang, et al.
Published: (2025-02-01)

An Open‐Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second‐Line Therapy for Advanced Head and Neck Squamous Cell Cancers
by: Vinod K. Ramani, et al.
Published: (2025-01-01)

A decade-long overview of adverse events in a tertiary surgical service in South Africa
by: H Wain, et al.
Published: (2024-10-01)

A Clinico-Epidemiological Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Centre of Eastern India
by: Sujata Sinha, et al.
Published: (2024-01-01)

Impact of discontinuation of cephazolin prophylaxis on the incidence of postoperative adverse events in cataract surgery
by: Kazutaka Uchida, et al.
Published: (2025-01-01)

The risks of adverse events with mirtazapine for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis
by: Caroline Barkholt Kamp, et al.
Published: (2025-01-01)

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database
by: Qian Qiao, et al.
Published: (2025-01-01)

Pharmacotherapy, adverse drug reactions, and factors associated with clinical outcome in primary open-angle glaucoma
by: Anushree Dayanand, et al.
Published: (2025-01-01)

PSA LEVEL AND ADVERSE EVENTS IN SIXTH AND TENTH SERIES DOCETAXEL CHEMOTHERAPY IN CASTRATE-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
by: Kurnia Penta Seputra, et al.
Published: (2025-01-01)

Examining vaccination-related adverse events in frequent neurodegenerative diseases
by: Shabnam Sodagari, et al.
Published: (2025-02-01)

Secondary Trigeminal Neuralgia after a Brainstem Hemorrhagic Stroke with Adverse Reaction to Carbamazepine: A Case Report
by: I Gusti Agung Ayu Andra Yusari, et al.
Published: (2024-12-01)